LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly signs $3 billion Haisco deal to boost drug discovery
Eli Lilly partnered with Chinese drugmaker Haisco Pharmaceutical to develop innovative medicines across multiple therapeutic areas. The collaboration focuses...
Eli Lilly cuts lung cancer recurrence risk 83% in landmark Retevmo trial
Eli Lilly reported that its targeted therapy Retevmo significantly improved outcomes in the Phase 3 LIBRETTO-432 trial. The drug reduced the risk of disease...
Eli Lilly showcases Foundayo data, beating oral semaglutide in weight loss
Eli Lilly and Company will present new cardiometabolic data at the American Diabetes Association's 86th Scientific Sessions from June 5-8. The presentations...
Eli Lilly Challenges Pfizer, Reporting Positive Bladder Cancer Drug Data
Eli Lilly presented Phase 1 trial results for its antibody-drug conjugate LY4052031 at the ASCO Annual Meeting. The drug treats advanced or metastatic...
🔴 LLY is trading 3% down today on profit-taking after obesity-drug reimbursement wins
LLY is trading 3% down at $1092.74 as investors lock in gains following a sharp rally driven by positive obesity-drug developments. • The pullback comes after...
Eli Lilly secures full PBM coverage for Zepbound, ending CVS exclusion
Eli Lilly secured coverage for obesity drugs Zepbound and Foundayo from all three major U.S. pharmacy benefit managers. CVS Caremark will add both medications...
Eli Lilly Price Target Lifted to $1,251 at BofA on Weight-Loss Drug Optimism
BofA Securities raised its price target for Eli Lilly (LLY) to $1,251 from $1,133. The bank maintained its "Buy" rating on the stock. A positive outlook for...
Eli Lilly buys three biotechs for $4 billion, returning to vaccines
Eli Lilly and Company will acquire Curevo Inc., LimmaTech Biologics, and Vaccine Company. The combined acquisitions total nearly $4 billion. This strategy...
Eli Lilly cuts cholesterol 62% with gene-editing therapy, sustaining 18-month results
Eli Lilly reported positive Phase 1b Heart-2 trial results for VERVE-102, an investigational gene-editing therapy for high-risk cardiovascular patients. A...
Eli Lilly Achieves 28% Weight Loss in Trial, Rivaling Bariatric Surgery
Eli Lilly announced Thursday that its experimental obesity drug, retatrutide, met all primary and secondary endpoints in a pivotal Phase 3 trial. The...
Eli Lilly and Dell Technologies Highlight Collaboration on AI-Driven Drug Discovery and Manufacturing
Eli Lilly and Company utilizes Dell Technologies' infrastructure to advance its AI-driven drug discovery and global manufacturing. The partners highlighted...
🟢 LLY is trading 3.1% up today, rebounding from drug pricing policy concerns
LLY is trading 3.1% up today at $1018.76, recovering from a previous session sell-off triggered by concerns over potential expansions to discounted drug...
Eli Lilly's Legal Case Concludes as Supreme Court Declines to Hear Appeal on Medicaid Award
On May 18, 2026, the U.S. Supreme Court declined to review a Medicaid award case involving Eli Lilly. This denial upholds the lower court's judgment against...
Eli Lilly GLP-1 sales to top $60 billion, fueled by overseas demand
Morgan Stanley projects Eli Lilly’s GLP-1 franchise will outperform 2026 consensus forecasts. The firm estimates 2026 worldwide revenue at $60.3 billion....
🟢 LLY is trading 3.1% up today on positive late-stage trial data for oral obesity pill Foundayo
LLY is trading at $1020.53 (+3.1%) following positive late-stage trial results for its oral obesity medication, Foundayo, which demonstrated sustained weight...
Eli Lilly defends obesity lead, as oral pill Foundayo sustains weight loss
Eli Lilly released positive late-stage trial results demonstrating long-term weight loss maintenance after switching from high-dose injectable GLP-1...
Eli Lilly Launches Alzheimer’s Drug in India, Eyes Manufacturing Hub
Eli Lilly and Company launched its Alzheimer's drug, Donanemab, in India under the brand name Lormalzi. India's Central Drugs Standard Control Organization...
I need to research the current situation with Eli Lilly, the Foundayo launch, and recent market dynamics.
Eli Lilly's Weight-Loss Pill Stumbled Out of the Gate — Can a $5 Billion Rebound Hold Without Stronger Prescriptions? Shares shifted as Eli Lilly climbed...
🟢 LLY is trading 3.03% up today as Foundayo launch pressure eases
LLY is trading at $996.28 (+3.03%) as bearish pressure from the Foundayo launch eases, fueling a continued rebound from Friday's lows. • The stock is showing...
🟢 LLY is trading 3% up today as bearish pressure from its Foundayo launch eases
LLY is trading at $977.58 (+3.07%) as bearish pressure from the recent Foundayo launch eases, allowing the stock to stage a modest rebound from Friday's...